Literature DB >> 8663

[Interrelations between blood pressure, blood volume, plasma renin and urinary catecholamines during beta-blockade in essential hypertension (author's transl)].

P Weidmann, C Beretta-Piccoli, W Ziegler, D Hirsch, R D de Châtel, F C Reubi.   

Abstract

Studies in 55 patients with benign essential hypertension showed that the beta-blockers bufuralol (22 patients) and propranolol (33 patients) at a dose ratio of 1:4, possess comparable antihypertensive efficacy despite different properties regarding intrinsic sympathomimetic activity. Beta-blocker-monotherapy normalized blood pressure ( less than 140/90 mm Hg) in one fourth of the patients. Body weight and plasma and blood volumes remained unchanged during beta-blockade of four to six weeks duration, the mean plasma potassium was slightly increased. The inhibition of plasma renin activity (PRA) was more pronounced with propranolol (-69%) than with bufuralol (-47%). Wirth both beta-blockers decreases in blood pressure correlated inversely with pre-treatment PRA (p less than 0.05). Propranolol-induced changes in blood pressure correlated also with associated changes in PRA (p less than 0.005); in contrast, no such relationship was observed with bufuralol. The blood pressure effects of bufuralol, however, correlated significantly with changes in urinary noradrenaline excretion (r=0.41; p less than 0.05). Patient sub-groups with low, normal or high pre-treatment PRA in the average showed a comparable pattern of pre-treatment noradrenaline excretion and patients with normal renin levels exreted more adrenaline than those with low renin levels (p less than 0.001). These data are consistent with the concept that in untreated essential hypertension PRA may be an index of adrenergic activiity, the latter representing an important determinant of blood pressure response to beta-blockade. The blood pressure lowering effects of bufuralol in benign essential hypertension seem to be independent of renin and may be related, at least partly, to diminished free peripheral noradrenaline levels.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 8663     DOI: 10.1007/BF01614293

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  43 in total

1.  Effect on aging on plasma renin and aldosterone in normal man.

Authors:  P Weidmann; S De Myttenaere-Bursztein; M H Maxwell; J de Lima
Journal:  Kidney Int       Date:  1975-11       Impact factor: 10.612

2.  Neurogenic factors in human hypertension: mechanism or myth?

Authors:  V DeQuattro; Y Miura
Journal:  Am J Med       Date:  1973-09       Impact factor: 4.965

3.  Vasoconstriction-volume analysis for understanding and treating hypertension: the use of renin and aldosterone profiles.

Authors:  J H Laragh
Journal:  Am J Med       Date:  1973-09       Impact factor: 4.965

4.  Adrenergic receptor mediation of renin secretion.

Authors:  N Winer; D S Chokshi; M S Yoon; A D Freedman
Journal:  J Clin Endocrinol Metab       Date:  1969-09       Impact factor: 5.958

5.  Plasma renin and blood pressure during treatment with methyldopa.

Authors:  P Weidmann; D Hirsch; M H Maxwell; R Okun; P Schroth
Journal:  Am J Cardiol       Date:  1974-11       Impact factor: 2.778

6.  Sympathetic innervation of the juxtaglomerular cells of the kidney.

Authors:  J Wågermark; U Ungerstedt; A Ljungqvist
Journal:  Circ Res       Date:  1968-02       Impact factor: 17.367

7.  Central hypotensive activity of dl- and d-propranolol.

Authors:  G J Kelliher; J P Buckley
Journal:  J Pharm Sci       Date:  1970-09       Impact factor: 3.534

Review 8.  Adverse reactions to beta-adrenergic receptor blocking drugs: a report from the Boston collaborative drug surveillance program.

Authors:  D J Greenblatt; J Koch-Weser
Journal:  Drugs       Date:  1974       Impact factor: 9.546

9.  Beta-adrenergic receptor blocking drugs, hypertension and plasma renin.

Authors:  T O Morgan; R Roberts; S L Carney; W J Louis; A E Doyle
Journal:  Br J Clin Pharmacol       Date:  1975-04       Impact factor: 4.335

10.  The influence of potassium administration and of potassium deprivation on plasma renin in normal and hypertensive subjects.

Authors:  H R Brunner; L Baer; J E Sealey; J G Ledingham; J H Laragh
Journal:  J Clin Invest       Date:  1970-11       Impact factor: 14.808

View more
  6 in total

1.  [Behaviour of plasma renin activity during long-term treatment with propranolol (author's transl)].

Authors:  H Witzgall; D Klaus; B Braun; H Ebel; J Zehner
Journal:  Klin Wochenschr       Date:  1977-04-01

2.  Recent pathogenic aspects in essential hypertension and hypertension associated with diabetes mellitus.

Authors:  P Weidmann
Journal:  Klin Wochenschr       Date:  1980-10-01

3.  [The importance of changes in whole-body balance of sodium and noradrenaline in essential hypertension (author's transl)].

Authors:  R Lang; A Maxrath; U Laaser; K A Meurer; W Kaufmann
Journal:  Klin Wochenschr       Date:  1978-11-15

4.  Effects of chronic alpha and beta adrenoceptor blockade with labetalol on plasma catecholamines and renal function in hypertension.

Authors:  G Keusch; P Weidmann; W H Ziegler; R de Châtel; F C Reubi
Journal:  Klin Wochenschr       Date:  1980-01-02

5.  Comparative evaluation of the new vasodilator carprazidil and minoxidil in the treatment of moderate to severe hypertension.

Authors:  M G Bianchetti; P Weidmann; K Boehringer; L Link; H Schiffl; C Beretta-Piccoli; J P Colombo
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

6.  Interference by sulphinpyrazone with the antihypertensive effects of oxprenolol.

Authors:  L A Ferrara; M Mancini; T Marotta; F Pasanisi; M L Fasano
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.